NDC 72065-001 Keveyis

Dichlorphenamide

NDC Product Code 72065-001

NDC CODE: 72065-001

Proprietary Name: Keveyis What is the Proprietary Name?
The proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.

Non-Proprietary Name: Dichlorphenamide What is the Non-Proprietary Name?
The non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.

Drug Use Information

Drug Use Information
The drug use information is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate. This information is not individual medical advice and does not substitute for the advice of a health care professional. Always ask a health care professional for complete information about this product and your specific health needs.

  • This medication is used to treat a certain inherited condition that causes attacks of muscle weakness or loss of muscle movement that come and go (primary periodic paralysis). Dichlorphenamide belongs to a class of drugs known as carbonic anhydrase inhibitors. It is not known how it works for this condition, but it can decrease the number of attacks of muscle weakness.

Product Characteristics

Color(s):
WHITE (C48325)
Shape: ROUND (C48348)
Size(s):
6 MM
Imprint(s):
D;50
Score: 2

NDC Code Structure

  • 72065 - Xeris Pharmaceuticals, Inc.

NDC 72065-001-01

Package Description: 100 TABLET in 1 BOTTLE

NDC Product Information

Keveyis with NDC 72065-001 is a a human prescription drug product labeled by Xeris Pharmaceuticals, Inc.. The generic name of Keveyis is dichlorphenamide. The product's dosage form is tablet and is administered via oral form. The RxNorm Crosswalk for this NDC code indicates multiple RxCUI concepts are associated to this product: 1661799 and 197594.

Dosage Form: Tablet - A solid dosage form containing medicinal substances with or without suitable diluents.

Product Type: Human Prescription Drug What kind of product is this?
Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.

Keveyis Active Ingredient(s)

What is the Active Ingredient(s) List?
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.


Inactive Ingredient(s)

About the Inactive Ingredient(s)
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product.

  • LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)
  • MAGNESIUM STEARATE (UNII: 70097M6I30)
  • STARCH, CORN (UNII: O8232NY3SJ)

Administration Route(s)

What are the Administration Route(s)?
The translation of the route code submitted by the firm, indicating route of administration.

  • Oral - Administration to or by way of the mouth.

Pharmacological Class(es)

What is a Pharmacological Class?
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

  • Carbonic Anhydrase Inhibitors - [MoA] (Mechanism of Action)
  • Sulfonamides - [CS]
  • Carbonic Anhydrase Inhibitor - [EPC] (Established Pharmacologic Class)

Product Labeler Information

What is the Labeler Name?
Name of Company corresponding to the labeler code segment of the Product NDC.

Labeler Name: Xeris Pharmaceuticals, Inc.
Labeler Code: 72065
FDA Application Number: NDA011366 What is the FDA Application Number?
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.

Marketing Category: NDA - A product marketed under an approved New Drug Application. What is the Marketing Category?
Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Start Marketing Date: 12-13-2021 What is the Start Marketing Date?
This is the date that the labeler indicates was the start of its marketing of the drug product.

Listing Expiration Date: 12-31-2022 What is the Listing Expiration Date?
This is the date when the listing record will expire if not updated or certified by the product labeler.

Exclude Flag: N - NO What is the NDC Exclude Flag?
This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA"s requests for correction to deficient or non-compliant submissions ("Y"), or because the listing certification is expired ("E"), or because the listing data was inactivated by FDA ("I"). Values = "Y", "N", "E", or "I".

* Please review the disclaimer below.

Keveyis Product Labeling Information

The product labeling information includes all published material associated to a drug. Product labeling documents include information like generic names, active ingredients, ingredient strength dosage, routes of administration, appearance, usage, warnings, inactive ingredients, etc.

Product Labeling Index

1 Indications And Usage

KEVEYIS is indicated for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants.

2.1 Dosage Information

Initiate dosing at 50 mg by mouth once or twice daily. The dosage may be increased or decreased based on individual response, at weekly intervals (or sooner in case of adverse reaction). The minimum recommended total daily dosage is 50 mg, and the maximum recommended total daily dosage is 200 mg.

2.2 Monitoring To Assess Effectiveness

Primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants are a heterogeneous group of conditions, for which the response to KEVEYIS may vary. Therefore, prescribers should evaluate the patient's response to KEVEYIS after 2 months of treatment to decide whether KEVEYIS should be continued.

2.3 Monitoring To Assess Safety

Baseline and periodic measurements of serum potassium and serum bicarbonate during KEVEYIS treatment is recommended


[see


Warnings and Precautions (5.3,


5.4)].

3 Dosage Forms And Strengths

Round, white tablets, scored on one side, engraved with "D" above the score and "50" below the score, the other side is plain, 50 mg each.

4 Contraindications

  • KEVEYIS is contraindicated in the following circumstances:Hypersensitivity to dichlorphenamide or other sulfonamides
  • [see
  • Warnings and Precautions (5.1)]
  • Concomitant use of KEVEYIS and high dose aspirin
  • [see
  • Warnings and Precautions (5.2) and
  • Drug Interactions (7.1)]
  • Severe pulmonary disease, limiting compensation to metabolic acidosis caused by KEVEYIS
  • [see
  • Warnings and Precautions (5.4)]
  • Hepatic insufficiency: KEVEYIS may aggravate hepatic encephalopathy.

5.1 Hypersensitivity And Other Life-Threatening Reactions

Fatalities associated with the administration of sulfonamides have occurred because of adverse reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia and other blood dyscrasias. Pulmonary involvement can occur in isolation or as part of a systemic reaction.KEVEYIS should be discontinued at the first appearance of skin rash or any sign of immune-mediated or other life-threatening adverse reaction.

5.2 Concomitant Use Of Aspirin Or Other Salicylates

Carbonic anhydrase inhibitors, including KEVEYIS, can cause metabolic acidosis


[see


Warnings and Precautions (5.4)]


, which can increase the risk of salicylate toxicity. Anorexia, tachypnea, lethargy, and coma have been reported with concomitant use of dichlorphenamide and high-dose aspirin. Therefore, the concomitant use of KEVEYIS and high-dose aspirin is contraindicated. Patients with concomitant use of KEVEYIS and low-dose aspirin should be carefully monitored.

5.3 Hypokalemia

KEVEYIS increases potassium excretion and can cause hypokalemia. The risk of hypokalemia is greater when KEVEYIS is used in patients with conditions associated with hypokalemia (e.g., adrenocortical excess, renal tubular acidosis type 1 and 2), and in patients receiving other drugs that may cause hypokalemia


[see


Drug Interactions (7.3)]


.


Baseline and periodic measurements of serum potassium during KEVEYIS treatment is recommended.If hypokalemia develops or persists, consideration should be given to reducing the dose or discontinuing KEVEYIS and correction of potassium levels.

5.4 Metabolic Acidosis

KEVEYIS can cause hyperchloremic non-anion gap metabolic acidosis. Concomitant use of KEVEYIS with other drugs that cause metabolic acidosis may increase the severity of acidosis. Concomitant use of KEVEYIS in compensated patients with respiratory acidosis, such as in advanced lung diseases, may lead to respiratory decompensation.Baseline and periodic measurements of serum bicarbonate during KEVEYIS treatment are recommended.
If metabolic acidosis develops or persists, consideration should be given to reducing the dose or discontinuing KEVEYIS


[see


Drug Interactions (7.4)]


.

5.5 Falls

KEVEYIS increases the risk of falls. The risk of falls is greater in the elderly and with higher doses of KEVEYIS. Consider dose reduction or discontinuation of KEVEYIS in patients who experience falls while treated with KEVEYIS.

6 Adverse Reactions

  • The following serious adverse reactions are described elsewhere in labeling:Hypersensitivity and Other Life-Threatening Reactions
  • [see
  • Warnings and Precautions (5.1)]
  • Hypokalemia
  • [see
  • Warnings and Precautions (5.3)]
  • Metabolic Acidosis
  • [see
  • Warnings and Precautions (5.4)]
  • Falls
  • [see
  • Warnings and Precautions (5.5)]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.In a 9-week randomized controlled trial in adults with hyperkalemic or hypokalemic periodic paralysis (Study 1), the most common adverse reactions in patients treated with KEVEYIS, with rates greater than placebo, were paresthesia, cognitive disorder, dysgeusia, and confusional state. The mean dose of KEVEYIS was 94 mg/day in patients with hypokalemic periodic paralysis and 82 mg/day in patients with hyperkalemic periodic paralysis.Table 1 lists the incidence of adverse reactions that occurred in ≥ 5% of patients treated with KEVEYIS and more commonly than in patients treated with placebo in Study 1.Table 1: Adverse Reactions in Patients Treated with KEVEYIS with Incidence ≥ 5% and more common than in Patients Treated with Placebo in Study 1Adverse ReactionKEVEYIS


N = 36


(%)


Placebo


N = 29


(%)


Nervous system disordersParesthesia4414Cognitive disorder


Cognitive disorder combined cases with the preferred terms of
cognitive disorder,
disturbance in attention, and
mental impairment.
147Dysgeusia140Confusional state110Headache87Hypoesthesia80Lethargy80Dizziness60Gastrointestinal disordersDiarrhea63Nausea60General disorders and administration site conditionsFatigue80Malaise60InvestigationsWeight decreased60Musculoskeletal and connective tissue disordersMuscle spasms80Arthralgia63Muscle twitching60RespiratoryDyspnea60Pharyngolaryngeal pain60SkinRash80Pruritus60

6.2 Postmarketing Experience

Adverse reactions have been identified during postapproval use of dichlorphenamide. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.The following are adverse reactions which have been reported during postapproval use of dichlorphenamide and were serious or are not reported in the previous section of labeling


[see


Clinical Trials Experience (6.1)]


: amnesia, cardiac failure, condition aggravated, convulsion, hallucination, nephrolithiasis, pancytopenia, psychotic disorder, renal tubular necrosis, stupor, syncope, tremor.

7.1 Aspirin And Other Salicylates

Carbonic anhydrase inhibitors, including KEVEYIS, can cause metabolic acidosis


[see


Warnings and Precautions (5.2,


5.4)],


which can increase the risk of salicylate toxicity. Anorexia, tachypnea, lethargy, and coma have been reported with concomitant use of dichlorphenamide and high-dose aspirin. Therefore, concomitant use of KEVEYIS and high-dose aspirin is contraindicated. Patients with concomitant use of KEVEYIS and low-dose aspirin should be carefully monitored


[see


Contraindications (4) and


Warnings and Precautions (5.2)].

7.2 Drugs That Are Substrates Of Organic Anion Transporter1 (Oat1)

In vitro, dichlorphenamide is an inhibitor of OAT1 transporters. The concomitant administration of KEVEYIS may increase the plasma exposures of OAT1 substrates. Use of KEVEYIS with  drugs that are sensitive to OAT1 inhibition (e.g., methotrexate, famotidine, oseltamivir) is not recommended


[see


Clinical Pharmacology (12.3)].

7.3 Drugs That Cause Hypokalemia

The risk of hypokalemia is greater with coadministration of KEVEYIS and other drugs that can cause hypokalemia (e.g., loop diuretics, thiazide diuretics, laxatives, antifungals, penicillins, and theophylline)


[see


Warnings and Precautions (5.3)]


.

7.4 Drugs That Cause Metabolic Acidosis

Coadministration of KEVEYIS and other drugs that can cause metabolic acidosis may increase the severity of the acidosis


[see


Warnings and Precautions (5.4)].

7.5 Drugs That Are Inhibitors Of Oat1 Or Oat3

An


in vitro transporter study indicated that dichlorphenamide is a substrate of human transporters OAT1 and OAT3


[see


Clinical Pharmacology (12.3)]


. Therefore, signs of dichlorphenamide toxicity should be monitored when administered with OAT1 or OAT3 inhibitors.

Other

Risk SummaryThere are no adequate data on the developmental risk associated with the use of KEVEYIS in pregnant women. A no-effect dose has not been established. Dichlorphenamide was teratogenic when administered orally to pregnant rats.


The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4%, and 15% to 20%, respectively.Clinical ConsiderationsFetal/Neonatal adverse reactionsKEVEYIS treatment can cause metabolic acidosis


[see


Warnings and Precautions (5.4)].


The effect of dichlorphenamide-induced metabolic acidosis has not been studied in pregnancy; however, metabolic acidosis in pregnancy (due to other causes) can cause decreased fetal growth, decreased fetal oxygenation, and fetal death, and may affect the fetus’ ability to tolerate labor. Pregnant patients should be monitored for metabolic acidosis and treated as in the nonpregnant state. Newborns of mothers treated with KEVEYIS should be monitored for metabolic acidosis because of possible occurrence of transient metabolic acidosis following birth.


Labor or DeliveryAlthough the effect of KEVEYIS on labor and delivery in humans has not been established, the development of dichlorphenamide-induced metabolic acidosis in the mother and/or in the fetus might affect the fetus’ ability to tolerate labor. 


DataAnimal DataTeratogenic effects (fetal limb reduction defects) were reported following oral administration of dichlorphenamide to pregnant rats during organogenesis at 350 mg/kg, or 17 times the maximum recommended human dose (200 mg/day) on a body surface area (mg/m


2) basis. A no-effect dose for adverse effects on embryofetal development has not been established.

Study 1Study 1 was a 9-week, double blind, placebo-controlled multi-center study. Study 1 consisted of two substudies: a substudy in patients with hypokalemic periodic paralysis (n=44), and a substudy in patients with hyperkalemic periodic paralysis (n=21). The primary efficacy endpoint in both substudies was the average number of self-reported attacks of muscle weakness per week over the final 8 weeks of the trial. Withdrawal from the study for acute severe worsening (increase in attack frequency or severity) was also assessed as an endpoint.In Study 1, the dose of KEVEYIS was 50 mg b.i.d. for treatment-naïve patients. Patients already on dichlorphenamide prior to the study continued on the same dose while on KEVEYIS during the study. In patients taking acetazolamide prior to the study, the dose of KEVEYIS was set at 20% of the acetazolamide dose. Dose reduction for tolerability was permitted.

Hypokalemic Periodic Paralysis Substudy of Study 1In the hypokalemic periodic paralysis substudy, median age of patients was 45 years and 73% of patients were male. Patients treated with KEVEYIS (n=24) had 2.2 fewer attacks per week than patients (n=20) treated with placebo (p=0.02). None of the patients randomized to KEVEYIS reached the endpoint of withdrawal from the study for acute worsening, vs. five patients randomized to placebo. The mean dose of KEVEYIS at Week 9 was 94 mg/day.

Hyperkalemic Periodic Paralysis Substudy of Study 1In the Hyperkalemic Periodic Paralysis substudy, median age of patients was 43 years and 43% of patients were male. During the double-blind treatment period, patients treated with KEVEYIS (n=12) had 3.9 fewer attacks per week than patients (n=9) treated with placebo (p=0.08). None of the patients randomized to KEVEYIS reached the endpoint of withdrawal from the study for acute worsening, vs. two patients randomized to placebo. The mean dose of KEVEYIS at Week 9 was 82 mg/day.

Study 2Study 2 was a 35-week, double blind, placebo-controlled, multi-center, two-period crossover study. Study 2 also consisted of two substudies: a substudy in patients with hypokalemic periodic paralysis (n=42), and a substudy in patients with hyperkalemic periodic paralysis (n=31), including patients with Paramyotonia Congenita. The primary endpoint in the hypokalemic periodic paralysis substudy was the incidence of acute intolerable worsening (based on attack frequency or severity) necessitating withdrawal. The primary endpoint in the hyperkalemic periodic paralysis substudy was the average number of self-reported attacks of muscle weakness per week. Dosing was determined similarly to Study 1.

Hypokalemic Periodic Paralysis Substudy of Study 2The hypokalemic periodic paralysis substudy included patients with a mean age of 38 years; 79% of patients were male. Acute intolerable worsening was observed in 2 patients on KEVEYIS vs. 11 patients on placebo (p=0.02). The mean dose of KEVEYIS at the end of the study was 96 mg/day.

Hyperkalemic Periodic Paralysis Substudy of Study 2The hyperkalemic periodic paralysis substudy included patients with a mean age of 37 years; and 79% of patients were male. Patients treated had 2.3 fewer attacks per week on KEVEYIS than on placebo (p=0.006). The mean dose of KEVEYIS at the end of the study was 73 mg/day.

Worsening of SymptomsAdvise patients to notify their physician if they experience acute worsening of symptoms of periodic paralysis.


Hypersensitivity and Other Life-Threatening ReactionsInform patients that hypersensitivity and immune mediated reactions can occur with KEVEYIS, and could be fatal.  Advise patients to discontinue KEVEYIS and notify their healthcare provider immediately if they develop a rash or signs and symptoms of anaphylaxis or other life-threatening reactions


[see


Warnings and Precautions (5.1)].


Drug InteractionsInstruct patients to notify their healthcare provider of all of the drugs and over-the-counter medications that they take and to not take aspirin or other salicylates without first discussing with their healthcare provider


[see


Drug Interactions (7.1,


7.2,


7.3,


7.4)].


Metabolic AcidosisInstruct patients to contact their healthcare provider immediately if they develop possible manifestations of metabolic acidosis (e.g., fast breathing, fatigue/tiredness, loss of appetite, or irregular heart beat or palpitations)


[see


Warnings and Precautions (5.4)].


FallsInform patients that KEVEYIS can increase their risk of falls


[see


Warnings and Precautions (5.5)].


Cognitive ImpairmentAdvise patients to notify their healthcare provider if they experience symptoms of cognitive impairment including confusion and memory lapse


[see


Adverse Reactions (6.1)].


Driving and Operating MachineryKEVEYIS may cause drowsiness/fatigue in some patients


[see


Adverse Reactions (6.1)]


. Caution patients on the potential for impaired ability to drive and operate machinery.

Manufactured by: Taro Pharmaceutical Industries Ltd., Haifa Bay, Israel 2624761Distributed by: Xeris Pharmaceuticals, Inc., Chicago, IL 60601KEVEYIS® is a registered trademark licensed exclusively in the US to Xeris Pharmaceuticals, Inc., a subsidiary of Xeris Biopharma, Inc. XERIS PHARMACEUTICALS® and its associated logo are trademarks of Xeris Pharmaceuticals, Inc.Copyright © 2021 Xeris Pharmaceuticals, Inc. All rights reserved.5200904-1021-02

8.2 Lactation

Risk SummaryThere are no data on the presence of dichlorphenamide in human milk, the effects on the breastfed infant, or the effects on milk production. 


The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for KEVEYIS and any potential adverse effects on the breastfed infant from KEVEYIS or from the underlying maternal condition.

8.4 Pediatric Use

Safety and effectiveness of KEVEYIS in pediatric patients have not been established.

8.5 Geriatric Use

The risk of falls and of metabolic acidosis are greater in elderly patients


[see


Warnings and Precautions (5.4,


5.5)]


​.

10 Overdosage

Symptoms of overdosage or toxicity may include drowsiness, anorexia, nausea, vomiting, dizziness, ataxia, tremor, and tinnitus.In the event of overdosage, induce emesis or perform gastric lavage. The electrolyte disturbances most likely to be encountered from overdosage are hypokalemia and hyperchloremic metabolic acidosis.

11 Description

KEVEYIS tablets contain dichlorphenamide, an oral carbonic anhydrase inhibitor. Dichlorphenamide, a dichlorinated benzenedisulfonamide, is known chemically as 4, 5–dichloro-1,3-benzenedisulfonamide.Its empirical formula is C


6H


6Cl


2N


2O


4S


2 and its structural formula is:


Dichlorphenamide USP is a white or practically white, crystalline compound with a molecular weight of 305.16. It is very slightly soluble in water but soluble in dilute solutions of sodium carbonate and sodium hydroxide. Dilute alkaline solutions of dichlorphenamide are stable at room temperature.KEVEYIS (dichlorphenamide) tablets are supplied as tablets, for oral administration, each containing 50 mg dichlorphenamide. Inactive ingredients are lactose monohydrate, magnesium stearate and pregelatinized starch.

12.1 Mechanism Of Action

Dichlorphenamide is a carbonic anhydrase inhibitor. However, the precise mechanism by which dichlorphenamide exerts its therapeutic effects in patients with primary periodic paralysis is unknown.

12.2 Pharmacodynamics

KEVEYIS can cause metabolic acidosis, which can increase the risk of salicylate toxicity with coadministration


[see


Warnings and Precautions (5.2)].


KEVEYIS-induced metabolic acidosis can also increase in severity with coadministration of other drugs that cause metabolic acidosis


[see


Warnings and Precautions (5.4)].

12.3 Pharmacokinetics

After single-dose administration in healthy subjects in fasted state, dichlorphenamide C


max and AUC increased in a dose-proportional manner within the range of 25 mg to 400 mg (2 times the maximum recommended dose). The steady-state is expected to be achieved within 10 days of twice-daily dosing.


AbsorptionThe median time to reach maximum concentration (T


max) of dichlorphenamide was about 1.5 to 3 hours postdose after both single and multiple dose administrations.


DistributionThe plasma protein binding of dichlorphenamide is approximately 88%.


EliminationFollowing a single-dose administration, mean terminal half-life was in the range of 32 to 66 hours.


MetabolismDichlorphenamide is not a substrate for CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 isoforms when tested


in vitro.


Drug Interaction StudiesIn vitro Assessment of Drug InteractionsDrug-Metabolizing Enzyme InhibitionDichlorphenamide is not an inhibitor for CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6, or 3A4 enzymes when tested


in vitro.


Drug-Metabolizing Enzyme InductionDichlorphenamide is not an inducer for CYP1A2, 2B6, or 3A4 enzymes when tested


in vitro.


In vitro Assessment of Transporter-Drug InteractionsDichlorphenamide is neither a substrate nor inhibitor for p-gp, BCRP, OATP1B1, OATP1B3, OAT2, OAT4, OCT1, OCT2, MATE1, or MATE2-K when tested


in vitro.


Dichlorphenamide is not an inhibitor of OAT3, but is an inhibitor of OAT1 based on


in vitro studies


[see


Drug Interactions (7.4)].


Dichlorphenamide is a substrate for transporters OAT1 and OAT3 based on


in vitro studies


[see


Drug Interactions (7.2)]


.



In Vivo Drug InteractionsThe use of dichlorphenamide in combination with high-dose aspirin is contraindicated as it may lead to salicylate toxicity. The mechanism(s) of this interaction is not known.


Specific PopulationsGeriatricsThe pharmacokinetics of dichlorphenamide in the elderly has not been determined.

Carcinogenesis & Mutagenesis & Impairment Of Fertility

CarcinogenesisStudies to assess the carcinogenic potential of dichlorphenamide have not been conducted.

MutagenesisStudies to assess the genotoxicity of dichlorphenamide have not been conducted.

Impairment of FertilityStudies to assess the effects of dichlorphenamide on fertility have not been conducted.

14 Clinical Studies

The efficacy of KEVEYIS was evaluated in two clinical studies, Study 1 and Study 2.

16 How Supplied/Storage And Handling

Each KEVEYIS (dichlorphenamide) tablet, 50 mg is round, white, scored on one side, engraved with "D" above the score and "50" below the score. The other side is plain.

KEVEYIS (dichlorphenamide) tablets are supplied as follows:

Bottles of 100......................................NDC 72065-001-01

Storage And Handling

Store at 20°C to 25°C (68°F to 77°F) [See USP Controlled Room Temperature].

* Please review the disclaimer below.